Enhancement of VP6 immunogenicity and protective efficacy against rotavirus by VP2 in a genetic immunization

López-Guerrero, Delia Vanesa; Arias, Nancy; Gutiérrez‐Xicoténcatl, Lourdes; Chihu-Amparan, Lilia; González, Alaín; Pedroza-Saavedra, Adolfo; Rosas-Salgado, Gabriela; Villegas-García, J. C.; Badillo, O.; Fernandez, G.; López, Susana; Esquivel-Guadarrama, Fernando

doi:10.1016/j.vaccine.2017.03.104

Cited by 8 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In RVA/Pig‐tc/CHN/SWU‐1C/2018/G9P[13], five genes (VP7, VP1, VP2, VP3 and NSP3) were closely related to the corresponding genes of human RVAs strain. VP6 is highly conserved and immunogenic, and can induce heterotypic protection in mice (Lopez‐Guerrero et al, 2018). We found that the VP6 gene of the SCMY‐A3 and SWU‐1C strains characterized in this study belongs to the I5 genotype, whereas that of the SCLSHL‐2‐3 strain was the I1 genotype, and was most similar to that of human RVA stain CHN/E931/2008 (98.4% amino acid similarity) (Table S1).…”

Section: Resultsmentioning

confidence: 99%

Genetic and immunological characterization of G9 group A porcine rotaviruses in China

Liu

Wang

Kan

et al. 2022

Zoonoses and Public Health

View full text Add to dashboard Cite

G9 group A rotaviruses (RVAs) are considered emerging pathogens in pigs and humans, and pigs are considered a potential host reservoir for human G9 RVAs. In this study, RVAs of two genotypes, G9P[23] and G9P[13], were successfully isolated and the genomic sequences were obtained, the genome constellation is G9‐P[23]‐I5‐R1‐C1‐M1‐A8‐N1‐T1‐E1‐H1 and G9‐P[13]‐I5‐R1‐C1‐M1‐A8‐N1‐T7‐E1‐H1 respectively. One strain which amplified from clinic faecal sample had an unique genome constellation G9‐P[23]‐I1‐R1‐C1‐M1‐A8‐N1‐T1‐E1‐H1. All the genomic segments of three porcine G9 RVAs were closely related to those of porcine and/or porcine‐like human RVAs, demonstrating that the three viruses were porcine–human reassortant strains. To study the immunogenicity of the porcine G9 RVAs, 6‐week‐old female BALB/c mice were immunized with inactivated vaccines derived from porcine RVAs and then mated. The highest titres of neutralizing antibodies against G9P[23] and G9P[13] porcine RVAs (1,291 ± 35.22 and 1:232 ± 39.28 respectively) were produced in mice 7 days after the second immunization. Suckling mice born to the vaccinated dams were protected by maternal antibodies against challenge with homologous strains. Overall, our data demonstrate the occurrence of porcine–human reassortants of G9 RVAs, and extend our understanding of the immunogenicity of porcine G9 rotaviruses. They also provide a basis for the development of a porcine G9 RVA vaccine.

show abstract

Section: Resultsmentioning

confidence: 99%

Genetic and immunological characterization of G9 group A porcine rotaviruses in China

Liu

Wang

Kan

et al. 2022

Zoonoses and Public Health

View full text Add to dashboard Cite

show abstract

“…Various RV VP6 Ag-encoding vaccine modalities, including DNA vaccines [ 3 , 26 – 28 , 36 , 56 , 57 , 60 , 74 , 121 , 123 , 125 , 128 ], subunit vaccines (harboring recombinant VP6 protein) [ 2 , 3 , 29 – 35 , 40 , 46 , 60 , 66 , 83 – 85 , 107 , 116 , 117 , 121 , 124 , 127 ], and self‐assembled structures [ 3 , 15 , 16 , 18 , 44 , 60 , 64 , 76 – 78 , 95 , 108 , 110 , 121 ] have been reported to induce an immune response and/or protection in animal models. The results of these animal immunization studies have indicated that, even in the absence of neutralizing Abs, immune responses to VP6 alone might be protective.…”

Section: Vp6 Immunogenicitymentioning

confidence: 99%

Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials

et al. 2022

View full text Add to dashboard Cite

The first-generation, live attenuated rotavirus (RV) vaccines, such as RotaTeq and Rotarix, were successful in reducing the number of RV-induced acute gastroenteritis (AGE) and child deaths globally. However, the low efficacy of these first-generation oral vaccines, coupled with safety concerns, required development of improved RV vaccines. The highly conserved structural protein VP6 is highly immunogenic, and it can generate self-assembled nano-sized structures, including tubes and spheres (virus-like particles; VLPs). Amongst the RV proteins, only VP6 shows these features. Interestingly, VP6-assembled structures, in addition to being highly immunogenic, have several other useful characteristics that could allow them to be used as adjuvants, immunological carriers, and drug-delivery vehicles as well as acting a scaffold for production of valuable nano-biomaterials. This review provides an overview of the self-assembled nano-sized structures of VP6-tubes/VLPs and their various functions.

show abstract

“…However, the co‐inoculation of pcDNA3‐VP2 and pcDNA3‐VP6 was found to induce a better immune response against RV infection when compared with individual plasmids. In particular, inoculated mice with 1:10 ratio of pcDNA3‐VP2 and pcDNA3‐VP6 showed higher protection level (58%), which clearly indicates that VP2 can potentiate the immunogenicity and protective efficacy of VP6 . Several approaches have been applied to improve DNA vaccine efficacy such as advancements in DNA vaccine vector design, the inclusion of genetically engineered cytokine adjuvants, and novel non‐mechanical delivery methods.…”

Section: Vp6 Immunogensmentioning

confidence: 99%

Rotavirus VP6 as a potential vaccine candidate

Afchangi

Jalilvand

Mohajel

et al. 2019

Reviews in Medical Virology

View full text Add to dashboard Cite

Summary By the age of 5 years, virtually all children have been infected by group A rotavirus (RVA), which is responsible for around half million mortality annually prior to vaccination. Relatively high rate of the morbidity and mortality highlights the necessity of applying preventive procedures particularly in developing countries. Two live attenuated RVA vaccines (Rotarix and RotaTeq) are licensed and now being used in many countries worldwide. Although these vaccines are shown to reduce the mortality up to 50%, several key questions yet remained to answer. Indeed, the licensed RV vaccines were found to be less effective in countries of sub‐Saharan Africa and Southeast Asia. Therefore, developing next generation RVA vaccines is warranted. VP6 is highly abundant and conserved protein that forms the middle layer of RV particles and was shown to be both antigenic and immunogenic. Although it does not induce neutralizing antibodies, different VP6 preparations were found to induce homologous and cross‐reactive immune responses with partial protection from RVA replication. Although the molecular mechanisms are not fully elucidated, VP6‐based RVA vaccine candidates are worthy of further consideration. This review aims to focus on different aspects of VP6 protein and its potentiality for an alternative RV vaccine against RV disease.

show abstract

Enhancement of VP6 immunogenicity and protective efficacy against rotavirus by VP2 in a genetic immunization

Cited by 8 publications

References 27 publications

Genetic and immunological characterization of G9 group A porcine rotaviruses in China

Genetic and immunological characterization of G9 group A porcine rotaviruses in China

Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials

Rotavirus VP6 as a potential vaccine candidate

Contact Info

Product

Resources

About